Aclarion Inc (ACON) Stock Price, Quote & News

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs whi...

Industry: Health Information Services

Sector: Healthcare

Phone: 833 275 2266

Website: www.aclarion.com

Address:

8181 Arista Place, Suite 100, Broomfield, United States

Huskersnsaints Feb. 3 at 6:21 PM

$ACON on a positive note Acon is only down 99% from its 52 week high!!!!

0 · Reply

Huskersnsaints Feb. 3 at 6:00 PM

$ACON That that is shareholder support!!!! Nicely done managment!!!!! Nothing like a positive PR to only go red!!!!!

0 · Reply

Huskersnsaints Feb. 3 at 5:11 PM

$ACON Obviously the back to back share/dilution dumps has ruined this stock for now!!!!! along with the fact that managment owns almost zero shares!!!! decent news and it tanks!!!! Nicely done by managment!!!!!

0 · Reply

Apes_Strong Feb. 3 at 2:54 PM

$ACON no one going to trust their scam announcements after the criminal rug pull they performed

1 · Reply

Huskersnsaints Feb. 3 at 1:25 PM

$ACON so yesterday this stock drop early about .50 on about 40000 shares not with about 90000 premarket we basically get nothing very odd responce to the news!!!! I just have to believe managment has lost all credibility even if the news is positive!!!!!

0 · Reply

Huskersnsaints Feb. 3 at 12:02 PM

$ACON at this price and the cash this company has they need to buy back about a million shares to give this company a bit of credibility or at least management needs to buy some shares

1 · Reply

Huskersnsaints Feb. 3 at 11:50 AM

$ACON almost zero reaction to news this far that's very very odd even for this stock

0 · Reply

DARKP00L Feb. 3 at 11:19 AM

$ACON 06:11 on Feb. 03 2026 Aclarion Expands Nociscan Availability In Los Angeles, Partners With Source Healthcare To Support Growth And Real-World Evidence Generation #tradeideas

0 · Reply

KuruHabesha Feb. 3 at 11:18 AM

$ACON — Loading! If volume comes in, a fast double is very possible 🚀 No panic here — just patience and eyes on volume 👀📈

0 · Reply

Huskersnsaints Feb. 3 at 11:16 AM

$ACON well news at least that's something

0 · Reply

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Oct 22, 2025, 6:00 AM EDT - 3 months ago

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 9, 2025, 6:00 AM EDT - 4 months ago

Aclarion to Present at the LD Micro Main Event XIX

Jun 24, 2025, 7:00 AM EDT - 8 months ago

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

May 20, 2025, 6:00 AM EDT - 9 months ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 12, 2025, 7:34 AM EDT - 9 months ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Apr 29, 2025, 6:00 AM EDT - 10 months ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 23, 2025, 6:00 AM EDT - 10 months ago

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 6:00 AM EDT - 10 months ago

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 9, 2025, 7:00 AM EDT - 10 months ago

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 2, 2025, 6:00 AM EDT - 10 months ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 13, 2025, 9:25 AM EDT - 11 months ago

Aclarion Provides Shareholder Update

Mar 6, 2025, 9:35 AM EST - 11 months ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 3, 2025, 6:00 AM EST - 1 year ago

Aclarion Announces First Commercial Agreement with Scripps Health

Feb 20, 2025, 6:00 AM EST - 1 year ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 11, 2025, 7:58 AM EST - 1 year ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 6, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 4, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Nov 21, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 14, 2024, 5:00 PM EST - 1 year ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 6:57 AM EDT - 1 year ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 13, 2024, 8:30 AM EDT - 1 year ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 12, 2024, 6:57 AM EDT - 1 year ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 10, 2024, 6:57 AM EDT - 1 year ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 5, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aug 29, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 21, 2024, 7:57 AM EDT - 1 year ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 15, 2024, 9:48 AM EDT - 1 year ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 8:08 AM EDT - 1 year ago

Aclarion Announces First Commercial Agreement in Michigan

Aug 13, 2024, 9:07 AM EDT - 1 year ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 1 year ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Apr 25, 2024, 9:14 AM EDT - 1 year ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Feb 27, 2024, 3:22 PM EST - 2 years ago

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 2 years ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 5, 2024, 8:00 AM EST - 2 years ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Jan 22, 2024, 8:00 AM EST - 2 years ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Nov 27, 2023, 8:00 AM EST - 2 years ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 6, 2023, 8:00 AM EST - 2 years ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Oct 25, 2023, 8:30 AM EDT - 2 years ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 24, 2023, 8:45 AM EDT - 2 years ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Aug 25, 2023, 4:10 PM EDT - 2 years ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Jun 14, 2023, 11:27 AM EDT - 2 years ago

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Jun 8, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

May 30, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

May 23, 2023, 7:30 AM EDT - 2 years ago

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

Huskersnsaints Feb. 3 at 6:21 PM

$ACON on a positive note Acon is only down 99% from its 52 week high!!!!

0 · Reply

Huskersnsaints Feb. 3 at 6:00 PM

$ACON That that is shareholder support!!!! Nicely done managment!!!!! Nothing like a positive PR to only go red!!!!!

0 · Reply

Huskersnsaints Feb. 3 at 5:11 PM

0 · Reply

Apes_Strong Feb. 3 at 2:54 PM

$ACON no one going to trust their scam announcements after the criminal rug pull they performed

1 · Reply

Huskersnsaints Feb. 3 at 1:25 PM

0 · Reply

Huskersnsaints Feb. 3 at 12:02 PM

$ACON at this price and the cash this company has they need to buy back about a million shares to give this company a bit of credibility or at least management needs to buy some shares

1 · Reply

Huskersnsaints Feb. 3 at 11:50 AM

$ACON almost zero reaction to news this far that's very very odd even for this stock

0 · Reply

DARKP00L Feb. 3 at 11:19 AM

$ACON 06:11 on Feb. 03 2026 Aclarion Expands Nociscan Availability In Los Angeles, Partners With Source Healthcare To Support Growth And Real-World Evidence Generation #tradeideas

0 · Reply

KuruHabesha Feb. 3 at 11:18 AM

$ACON — Loading! If volume comes in, a fast double is very possible 🚀 No panic here — just patience and eyes on volume 👀📈

0 · Reply

Huskersnsaints Feb. 3 at 11:16 AM

$ACON well news at least that's something

0 · Reply

legaleagle96 Feb. 3 at 11:07 AM

$ACON hot trash

0 · Reply

batmantradingzz Feb. 3 at 11:01 AM

$RAYA sympathy to $ACON $CDT

0 · Reply

stevero Feb. 2 at 6:59 PM

$ACON Dirty Dogg Managment operates this as a RatHole Operation. This stock once again shows absolutely no support whatsoever, and for the umpteenth time is being driven down into the Sewer, only for another massive reverse split to occure. The Vermin element dominates this only extracting funds raised into their greedy pockets, sticking it to the little guy (bagholder). Dilutive Offerings bought have made the participants in them money, and likely will again do the same... rinse and repeat. Yet again ALL NEGATIVE on the stockholders, they're the Sucker Liquidity for the Greedy.

1 · Reply

Apes_Strong Feb. 2 at 6:26 PM

$ACON in keeping with criminal conduct the Thramann, Ness, Dawson syndicate will probably issue themselves a boatload of options at these prices The will be the straw that breaks their criminal backs

0 · Reply

brptrader Feb. 2 at 3:48 PM

$ACON back double digits soon, then reverse split. Rince repeat. Lots of money lost for the day traders

1 · Reply

Apes_Strong Feb. 2 at 3:43 PM

$ACON this is what happens when criminals control potential

0 · Reply

Dreamfield Feb. 2 at 3:25 PM

$ACON what is going on with this stock lol. Seemingly good product but scummy leadership?

0 · Reply

Apes_Strong Feb. 2 at 3:04 PM

$ACON lock them up lock them up lock them up

1 · Reply

Apes_Strong Feb. 2 at 2:43 PM

$ACON handcuffs handfcuffs handcuffs Put these criminals in jail where they belong

1 · Reply

Apes_Strong Feb. 2 at 2:35 PM

$ACON this will go up when Thramann, Ness and Dawson are taken out in handcuffs

1 · Reply

Apes_Strong Feb. 2 at 2:34 PM

$ACON $ADTX $AKAN $AMZD $AREB Stop with your nonsense There’s 2,850,000 shares and they are all free trading

1 · Reply

AtlasForce1 Jan. 31 at 5:40 AM

$ADTX $AREB $AMZD $ACON $AKAN Worth watching next week.

3 · Reply

Market Cap	2.83M
Revenue (ttm)	50,000.00
Net Income (ttm)	-6.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,980.00%
Debt to Equity Ratio	0.00

Volume	195,900
Avg Vol	1,044,510
Day's Range	N/A - N/A
Shares Out	854,000.00
Stochastic %K	7%
Beta	1.44
Analysts	Sell
Price Target	$23.00